The management of menopause in women with a history of endometriosis: a systematic review

L.C. Gemmell¹, K.E. Webster², S. Kirtley³, K. Vincent², K.T. Zondervan²,⁴, and C.M. Becker²,*

¹Case Western Reserve School of Medicine, 10900 Euclid Avenue, Cleveland, OH 44106, USA
²Endometriosis CaRe Centre, Nuffield Department of Obstetrics and Gynaecology, University of Oxford, John Radcliffe Hospital, Women’s Centre, Oxford OX3 9DU, UK
³Centre for Statistics in Medicine, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, Botnar Research Centre, Windmill Road, Oxford OX3 7LD, UK
⁴Wellcome Trust Centre for Human Genetics, University of Oxford, Roosevelt Drive, Oxford OX3 7BN, UK

*Correspondence address. E-mail: christian.becker@obs-gyn.ox.ac.uk

Submitted on January 9, 2017; resubmitted on April 7, 2017; editorial decision on April 18, 2017; accepted on May 4, 2017

TABLE OF CONTENTS

Introduction
Endometriosis and oestrogen dependence
Transition to menopause
Appropriateness of HRT

Methods
Search strategy
Inclusion criteria
Quality assessment
Data extraction
Data synthesis and analysis

Results
Included studies
Case reports and case series (33 studies; 48 patients)
Endometriosis recurrence in women on HRT (17 patients)
Malignant transformation (25 patients)
Observational studies and clinical trials (6 studies)
Should HRT be given to women with previous endometriosis?
Should HRT be given immediately following surgical menopause?
What menopausal treatments are most appropriate for women with previous endometriosis?

Discussion
Recurrence
Malignant transformation
Considerations regarding type and timing of HRT

Conclusion

Summary

© The Author 2017. Published by Oxford University Press on behalf of the European Society of Human Reproduction and Embryology.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
**BACKGROUND:** Endometriosis is typically regarded as a premenopausal disease, resolving after natural or iatrogenic menopause due to declining oestrogen levels. Nonetheless, case reports over the years have highlighted the incidence of recurrent postmenopausal endometriosis. It is now clear that both recurrence and malignant transformation of endometriotic foci can occur in the postmenopausal period. Postmenopausal women are commonly treated with hormone replacement therapy (HRT) to treat climacteric symptoms and prevent bone loss; however, HRT may reactivate endometriosis and stimulate malignant transformation in women with a history of endometriosis. Given the uncertain risks of initiating HRT, it is difficult to determine the best menopausal management for this group of women.

**OBJECTIVE AND RATIONAL:** The aim of this study was to systematically review the existing literature on management of menopausal symptoms in women with a history of endometriosis. We also aimed to evaluate the published literature on the risks associated with HRT in these women, and details regarding optimal formulations and timing (i.e. initiation and duration) of HRT.

**SEARCH METHODS:** Four electronic databases (MEDLINE via OVID, Embase via OVID, PsycINFO via OVID and CINAHL via EbscoHost) were searched from database inception until June 2016, using a combination of relevant controlled vocabulary terms and free-text terms related to ‘menopause’ and ‘endometriosis’. Inclusion criteria were: menopausal women with a history of endometriosis and menopausal treatment including HRT or other preparations. Case reports/series, observational studies and clinical trials were included. Narrative review articles, organizational guidelines and conference abstracts were excluded, as were studies that did not report on any form of menopausal management. Articles were assessed for risk of bias and quality using GRADE criteria.

**OUTCOMES:** We present a synthesis of the existing case reports of endometriosis recurrence or malignant transformation in women undergoing treatment for menopausal symptoms. We highlight common presenting symptoms, potential risk factors and outcomes amongst the studies. Sparse high-quality evidence was identified, with few observational studies and only two randomized controlled trials. Given this paucity of data, no definitive conclusions can be drawn concerning risk.

**WIDER IMPLICATIONS:** Due to the lack of high-quality studies, it remains unclear how to advise women with a history of endometriosis regarding the management of menopausal symptoms. The absolute risk of disease recurrence and malignant transformation cannot be quantified, and the impact of HRT use on these outcomes is not known. Multicentre randomized trials or large observational studies are urgently needed to inform clinicians and patients alike.

**Key words:** endometriosis / menopause / HRT / unopposed oestrogen / combined HRT / tibolone / recurrence / malignant transformation

---

**Introduction**

**Endometriosis and oestrogen dependence**

Endometriosis is a disease that affects an estimated 6–10% of reproductive aged women, totalling approximately 176 million women worldwide (Bulun, 2009). It is defined as the presence of endometrial-like tissue in extraterine locations and is a chronic condition associated with debilitating pelvic pain, dyspareunia, dysuria, dysmenorrhoea and infertility. However, due to a lack of reliable diagnostic tools and the non-specific nature of the symptoms, there exists a widely recognized delay in diagnosis of 8–10 years (Ahn et al., 2017). Consequently, the economic impact is substantial, as chronic and debilitating pain from endometriosis may hinder work productivity, while infertility can cause major psychosocial and financial strain to affected women and their partners (Simoens et al., 2007, 2012).

The pathophysiology of endometriosis is complex and not completely understood. Sampson’s retrograde menstruation theory, which states that endometrial cells travel backwards through the fallopian tubes during menses to reach the peritoneal cavity, has gathered the most robust support (Vercellini et al., 2014). Oestrogen dependence, progesterone resistance, inflammation and genetic predisposition represent some of the pathophysiological hallmarks of this disease (Burney and Giudice, 2012). The central feature is oestrogen-dependent growth. Endometriotic lesions pathologically overexpress oestrogen receptor beta (ERβ) (>100x higher expression compared to endometrial tissue) and have been demonstrated to express (i) high levels of steroidalgenic acute regulatory protein (StAR) and P450 aromatase, and (ii) reduced levels of 17β hydroxysteroid dehydrogenase Type 2. This expression profile results in locally elevated levels of the biologically active form of oestrogen (oestradiol) (Kitawaki et al., 2002; Bulun et al., 2012). These molecular studies are supported by clinical observations of disease regression, symptom relief and alleged ‘cures’ for endometriosis as women achieve a hypo-oestrogenic state through iatrogenic or natural menopause (Inceboz, 2015).

**Transition to menopause**

Understanding the altered hormonal milieu in endometriosis has enabled clinicians to exploit oestrogen dependence in their management, prescribing medications to suppress ovarian function or alter local oestrogenic effects. However, in severely symptomatic cases, first-line medical therapy (including the oral contraceptive pill or progesterogens) or laparoscopic excision of endometriotic lesions may prove insufficient, and induction of menopause via GnRH analogues or oophorectomy is indicated (Dunselman et al., 2014). Surgically or medically induced menopause is associated with a swift and dramatic fall in oestrogen levels. This decline may relieve endometriosis-related symptoms, but can simultaneously trigger menopausal symptoms. These symptoms are diverse and include hot flushes, vaginal dryness, sleep and mood disturbances, night sweats and painful intercourse, among others. While these symptoms occur in many women who naturally transition into menopause, they are especially prevalent and severe in women with a sudden onset of the hypoestrogenic state (Hendrix, 2005). The gold standard for treatment of
Menopausal symptoms have traditionally been hormone replacement therapy (HRT). HRT has been crucial for achieving symptom relief and improving the quality of life of millions of menopausal women, although these successes have been accompanied by safety concerns regarding specific preparations and dosages (Manson et al., 2013).

**Appropriateness of HRT**

Many studies have explored the efficacy and safety of HRT in postmenopausal women with climacteric symptoms (Rossouw et al., 2002; Rozenberg et al., 2013); however, few studies have investigated the use of hormonal therapy in postmenopausal women with a history of endometriosis. Two specific concerns are present in this group of women. Firstly, there is the possibility that exogenous oestradiol will reactivates growth of endometriotic deposits and cause symptomatic recurrence. Secondly, there is a concern that oestradiol will promote malignant transformation of residual endometriotic tissue. Sampson first described malignant transformation of ovarian endometriosis in 1925 (Sampson, 1925) and although its pathogenesis is not fully understood, oxidative stress, inflammation and an altered hormonal milieu have been implicated as contributing factors (Nezhat et al., 2014). Malignant transformation is thought to be a multistep pathway in which normal endometriotic tissue progresses to an atypical intermediate stage, and finally to invasive carcinoma (Gadducci et al., 2014). These sequential steps towards malignancy have been associated with genetic alterations in PTEN, TP53 and ARID1A and have been demonstrated in endometriosis-associated cancers (Munksgaard and Blaakaer, 2012). In a recent animal study using a rodent model of endometriosis (adult female Sprague-Dawley rats, aged 8–12 weeks), treatment with unopposed oestradiol successfully induced malignant transformation of endometriotic foci (Wang et al., 2015). Mechanistically, oestradiol affects PTEN expression in human endometrial cells and are associated with increased proliferation, direct cell damage and increased risk of acquiring somatic mutations (Turbiner et al., 2008).

However, the impact of declining oestradiol levels should not be underestimated. Menopausal symptoms affect the lives of millions of women worldwide. The hypo-oestrogenic state can significantly impair the quality of life by making sexual intercourse uncomfortable or painful, causing sleep deprivation, or resulting in mood changes. Furthermore, declining systemic oestradiol levels are a risk factor for cardiovascular and bone disease (Gallagher, 2007; Rosano et al., 2007). The use of HRT has been shown to reduce the risk of such conditions and improve the quality of life of symptomatic women (Langer, 2017).

The decision whether or not to prescribe HRT in general, and particularly in women with a history of endometriosis, is therefore a complex clinical decision and may also take into account other risk factors, such as residual disease after surgery (Clayton et al., 1999) and obesity which causes increased aromatase activity in peripheral tissues resulting in higher systemic oestrogen levels (Zanetta et al., 2000).

Our study aimed to conduct a systematic review of the literature investigating a critical question: What is the current evidence on the management of menopausal symptoms in women with a history of endometriosis? We aimed to cover the literature on a number of sub-questions, including: What are the various treatment options to manage menopausal symptoms in these women? What are the risks associated with HRT in this cohort? Should HRT be given immediately following surgically induced menopause or be delayed? What preparations are most appropriate, and for how long should treatment be given? We aimed to synthesize the literature in a comprehensive manner, and hoped to aid the design of future research in this area. Given the prevalence of endometriosis and the inevitability of eventual menopause in these women, this is clearly an important question that warrants robust, evidence-based guidelines.

**Methods**

This systematic review was registered and accepted for inclusion in PROSPERO (Gemell et al., 2016) in July 2016 (PROSPERO ID number: CRD42016042024).

**Search strategy**

We searched four electronic databases (MEDLINE via OVID, Embase via OVID, PsycINFO via OVID and CINAHL via EbscoHost), from database inception until 26 June 2016, using a combination of relevant controlled vocabulary terms and free-text terms searched in the title or abstracts related to ‘menopause’ and ‘endometriosis’. No study type, language or date limits were applied to the search. An example of the search strategy used for the MEDLINE database is included in Supplementary Table S1.

**Inclusion criteria**

All retrieved studies were uploaded to EndNote and duplicates were deleted. One reviewer (L.G.) sifted the full library (titles/abstracts), and two reviewers (K.W., C.B.) sifted 10% of the library (randomly selected using EndNote Record Number) to assess concordance. The full text of potentially relevant articles was retrieved to assess whether the paper should be included. Inclusion criteria were that the study population included postmenopausal women with a confirmed, or clinically suspected, history of endometriosis, and the article discussed management of menopausal symptoms. All study designs were included (case reports, observational studies and clinical trials). We excluded articles that did not discuss any form of menopausal management (e.g. HRT, tibolone or other preparations). We excluded narrative review articles and organizational guidelines in an attempt to focus the review on primary literature. Conference abstracts were also excluded.

The reviewers shared their lists of included studies, and concordance was determined. When there were disparities in the list, consensus was reached through discussions between the reviewers.

**Quality assessment**

Quality of included studies was assessed independently by two reviewers (L.G., K.W.) using the GRADE criteria (Guyatt et al., 2011). Assigned ratings were compared and a third reviewer (C.B.) was consulted when there were disagreements.

**Data extraction**

Data were extracted into a standard form by one reviewer (L.G.). For case reports, the following information was extracted: patient age at presentation, presenting symptoms, ureteral involvement (yes or no), type (surgical vs. natural) and timing (years previously) of menopause, stage and extent of endometriosis before menopause, reported menopausal symptoms, treatment provided, duration of follow-up, method of outcome assessment, outcome (recurrence, malignant transformation, side effects, mortality) and recommendation (if provided).
For all other study types, information on study design, study objective, sample size, participants’ characteristics, intervention, method of outcome assessment, outcome, duration of follow-up and recommendation (if provided) was recorded.

### Data synthesis and analysis

The nature of the evidence retrieved by our search (predominantly case reports, and a small number of heterogeneous observational studies and clinical trials) meant that meta-analysis was not possible, thus a narrative synthesis of the data is provided.

Where possible, if not reported in the original article, risk ratios (RRs) for specific outcomes were calculated using RevMan (Review Manager [Computer program]. Version 5.3 2014).

### Results

#### Included studies

Searches across all four databases retrieved 17,488 studies. Duplicates (5,008) were removed, leaving 12,480 studies (Fig. 1). After reading titles and abstracts, 12,366 failed to meet inclusion criteria. The full-text versions of the remaining 114 studies were read in their entirety. Of these 114 studies, 75 were excluded because they did not meet our inclusion criteria. This left 39 included studies: 33 case reports and 6 observational studies and clinical trials.

#### Case reports and case series (33 studies; 48 patients)

There were 32 case reports/series including 42 patients identified by our search. An additional article describing endometriosis-related malignancies in six women who had taken oestrogen replacement was retrieved (Leiserowitz et al., 2003). This article is discussed separately, as insufficient data are reported for the individual women to enable inclusion in our summary statistics.

Outcome evidence provided by these reports was assessed as very low quality given their observational nature and inherent risk of publication bias. Summary characteristics of the 42 patients are presented in Table 1. The age of included patients ranged between 30 and 75 years at presentation (mean age: 52 years). Of 42 patients, 40 had prior histories of endometriosis, either (i) confirmed by intraoperative visualization and/or histologically after laparoscopic excision (n = 34), (ii) suspected given the presence of symptoms (infertility,

![Figure 1](https://academic.oup.com/humupd/article-abstract/23/4/481/3814217/fig1)

**Figure 1** Flow diagram depicting inclusion and exclusion decisions throughout the review process.
pelvic pain, menorrhagia) \((n = 2)\), or (iii) assessed by unspecified methodology \((n = 4)\). Two patients did not have premenopausal endometriosis diagnoses, but were speculated by the case report authors to have had such and are thus included in our analysis. There were 36 patients who went through a surgically induced menopause (procedures involving oophorectomy), and four patients went through menopause naturally (one of these four was diagnosed with premature ovarian insufficiency). An additional two patients are believed to have gone through natural menopause, and underwent oophorectomy at ages 57 and 60. HRT was given as treatment for \((n = 12)\) or prevention of \((n = 30)\) menopausal symptoms. The mean duration of HRT use prior to presentation was 7.8 years \((\text{range: 4 months to 20 years})\). Of 36 patients who had undergone hysterectomy, 31 used unopposed oestrogen therapy.

The two main outcomes reported were endometriosis recurrence \((n = 17)\) and malignant transformation \((n = 25)\). For analysis, case reports and series were divided by these two main outcomes. One case series was included in both outcomes as it described three patients with endometriosis recurrence and one patient with malignant transformation \((\text{Taylor et al., 1999})\).

### Endometriosis recurrence in women on HRT (17 patients)

Thirteen case reports and case series were identified reporting endometriosis recurrence in menopausal women given HRT for the treatment or prevention of menopausal symptoms. These included 17 patients between the ages of 30–65 \((\text{median age: 46 years})\) \((\text{Table II})\).

All of the included women had undergone treatment with exogenous oestrogens in some form. \(\text{Skor et al., 1977}\) was the earliest report retrieved by our search. This case was a 48-year-old Caucasian woman who presented with a 2-month history of painless haematuria and decreased urinary stream on voiding. She had undergone a total abdominal hysterectomy with bilateral salpingo-oophorectomy \((\text{TAH + BSO})\) with endometriosis found in the specimen and confirmed by histology. She had been prescribed conjugated oestrogens \((\text{Premarin 1.25 mg/day})\) following surgery and continued these for 6 years until her presentation. On physical examination, a 7 cm \(\times\) 8 cm mass starting in the midline and extending to the left pelvic wall was palpated and the patient underwent cystoscopy. Postmenopausal bladder endometriosis was diagnosed histologically. Oestrogens were discontinued and intramuscular medroxyprogesterone acetate \((1 \text{ gm per week})\) was administered for 2 months. Despite this, there was no significant alteration in the size of the mass. Shortly afterwards, due to symptom recurrence, the endometriotic lesion was removed surgically. The patient had no complaints 1-year post treatment. The authors commented that exogenous oestrogens play a role in the stimulation and development of postmenopausal endometriosis.

Sixteen other similar accounts were retrieved from our search, with the latest report published in 2009 \((\text{Giarenis et al., 2009})\). The majority of cases \((12 \text{ out of 17})\) were women with a prior hysterectomy, who took unopposed oestrogen. The remaining cases of recurrence were in women who took combined HRT.

### Severity of prior endometriosis and menopause

Six patients had a history of ‘extensive’ or ‘severe’ endometriosis \((\text{Manyonda et al., 1989; Joseph et al., 1994; Taylor et al., 1999; Badawy et al., 2004})\). Fourteen patients underwent surgical menopause years before presentation \((\text{Skor et al., 1977; Stewart and Ireland, 1977; Kapadia et al., 1984; Ray et al., 1985; Manyonda et al., 1989; Joseph et al., 1994; Taylor et al., 1999, 2005; Badawy et al., 2004; Giarenis et al., 2009})\), while only two transitioned naturally to menopause \((\text{Goh and Hall, 1992; Chaíne et al., 2007})\). One patient entered menopause as a result of premature ovarian insufficiency \((\text{Mattar et al., 2008})\). The median time between surgical menopause and presentation was 7.1 years \((\text{range: 4 months to 13 years})\).

### Menopausal management

Unopposed oestrogen was implicated in numerous cases of symptom recurrence \((n = 12)\) \((\text{Skor et al., 1977; Stewart and Ireland, 1977; Kapadia et al., 1984; Ray et al., 1985; Manyonda et al., 1989; Taylor et al., 1999, 2005; Badawy et al., 2004; Giarenis et al., 2009})\). Fewer studies reported recurrence in women who were using combined hormonal preparations \((\text{oestrogen and progestagen})\) \((n = 5)\) \((\text{Goh and Hall, 1992; Joseph et al., 1994; Badawy et al., 2004; Chaíne et al., 2007; Mattar et al., 2008})\). In terms of method of oestrogen administration, oral tablets \((n = 5)\) \((\text{Skor et al., 1977; Stewart and Ireland, 1977; Kapadia et al., 1984; Ray et al., 1985; Goh and Hall, 1992})\), implants \((n = 6)\) \((\text{Manyonda et al., 1989; Taylor et al., 1999, 2005})\) and patches \((n = 3)\) \((\text{Badawy et al., 2004; Taylor et al., 2005})\) were all reported. \(\text{Table III}\) provides information on HRT dosages and regimens; however, variability in the level of detail provided by the included case reports and series limits these data.

### Presenting symptoms and sites of recurrence

As may be expected, endometriosis recurrence commonly presented with pain \((n = 7)\); in locations typical of premenopausal endometriosis, i.e. abdomen \((\text{Taylor et al., 1999})\), iliac fossae \((\text{Manyonda et al., 1989; Goh and Hall, 1992})\), genitals \((\text{Taylor et al., 1999})\); and in more unusual sites such as the loin \((\text{Manyonda et al., 1989})\). Abnormal bleeding was also a common presentation \((n = 14)\), including postmenopausal vaginal bleeding \((\text{Taylor et al., 1999; Badawy et al., 2004; Giarenis et al., 2009})\), haematuria \((\text{Skor et al., 1977; Stewart and Ireland, 1977; Kapadia et al., 1984; Ray et al., 1985; Taylor et al., 2005})\), rectal bleeding \((\text{Taylor et al., 2005})\) and also haemoptysis \((\text{Joseph et al., 1994})\);
| Author, date (# patients) | Patient Age (years) | Presenting symptoms [ureter involvement] | Medical history and menopause | HRT [duration] | Diagnosis | Treatment [follow-up: patient status] |
|---------------------------|---------------------|----------------------------------------|-----------------------------|----------------|-----------|-------------------------------------|
| Skor et al. (1977) (N = 1) | 48                  | Painless haematuria + palpable bladder mass [No] | Endometriosis Surgical menopause | Oestrogen-only HRT Conjugated oestrogen tablets [6 years] | Postmenopausal bladder endometriosis | Discontinued oestrogens + initiated Depo-Provera + surgery [1 year: no complaints] |
| Stewart and Ireland (1977) (N = 1) | 65                  | Intermittent painless haematuria [No] | Leiomyoma, no confirmed history of endometriosis, but speculated by authors Unclear menopause (underwent TAH + right SO at age 59) | Oestrogen-only HRT Oestrogen tablets [3 years] | Bladder endometriosis extending into bowel | Surgery [6 weeks: cystoscopy revealed normal appearing bladder and bimanual examination was normal] |
| Kapadia et al. (1984) (N = 1) | 56                  | Painless haematuria; two episodes of gross haematuria 10 days before admission [Yes] | Uterine leiomyomas, bilateral endometriommas, right fallopian tube endometriosis Surgical menopause | Oestrogen-only HRT | Postmenopausal ureteral endometriosis | Surgery [18 months: no complaints] |
| Ray et al. (1985) (N = 1) | 64                  | Painless haematuria [Yes] | Right ovarian endometriosis Surgical menopause | Oestrogen-only HRT Conjugated oestrogen tablets ['long term'] | | |
| Manyonda et al. (1989) (N = 2) | (1) 47 (2) 39       | (1) Three day history of vomiting and right iliac fossa pain [Yes] (2) Two day history of severe left loin and left iliac fossa pain [Yes] | (1) Bilateral ovarian endometriosis (2) Extensive endometriosis Both surgical menopause | Oestrogen-only HRT (1) Oestradiol implant, ethinyl oestriadiol [5 years, 3 days 2 weeks prior to presentation] (2) Oestradiol implant [9 years] | (1) Large chocolate cyst (3 cm in diameter) compressing ureter at bifurcation of iliac vessel (2) Chocolate cyst (3–4 cm in diameter), endometriosis in the cyst wall and end-stage adherent to adenomatous hyperplasia arising in endometriosis | (1) Surgery [2 years: no complaints, on Danazol] (2) Surgery [6 months: no complaints, on Danazol] |
| Goh and Hall (1992) (N = 1) | 54                  | 5-month history of left iliac fossa pain, especially during her monthly withdrawal bleeding [No] | Endometriosis suggested by symptoms: primary infertility and recurrent left iliac fossa pain Natural menopause | Combined HRT Conjugated oestrogen tablets + oral medroxyprogesterone [1 year] | 8 cm left ovarian endometrioma adherent to sigmoid colon—uterus had extensive endometrial deposits on serosal surface | Surgery [2 years: no complaints, on Premarin to treat menopausal symptoms] |
| Joseph et al. (1994) (N = 1) | 30                  | Recurrent haemoptysis and left-sided haemothorax [No] | Extensive pelvic endometriosis, pleural endometriosis Surgical menopause | Combined HRT Oestrogen and progesterone [4 months] | Recurrent thoracic endometriosis | Surgery [9 months: no complaints, advised to delay HRT] |
| Taylor et al. (1999) (N = 3) | (1) 42 (2) 40 (3) 38 | (1) Left abdominal pain and vaginal bleeding [Yes] (2) Severe lower abdominal pain [No] (3) Severe dyspareunia [No] | All had severe or extensive endometriosis All surgical menopause | Oestrogen-only HRT All used oestradiol implants (1) [3 years] (2) [2 years] (3) [2 years] | (1) Endometriotic mass in left pelvis obstructing ureter (2) Extensive pelvic endometriosis (3) Endometriosis of vaginal vault | (1) Surgery [6 years: no complaints, on continuous combined hormone replacement] (2) Surgery + discontinued oestradiol implant [Not specified] (3) Surgery [Not specified, on tibolone] |
| Badawy et al. (2004) (N = 2) | (1) 35 (2) 40       | (1) Vaginal bleeding that intensified and became constant, severe cramping [No] | (1) Severe chronic pelvic pain, dyspareunia, dysmenorrhoea, bilateral ovarian endometriosis | Oestrogen-only HRT and combined HRT (1) Oestradiol patch followed by various regimes of | Both—endocervical endometriosis | (1) Surgery [Not specified] (2) Surgery [Not specified, on ERT] |

Table II: Case reports and series reporting the postmenopausal recurrence of endometriosis after HRT in women with a history of endometriosis.
(2) Worsening vaginal bleeding of several months duration [No]  
(2) Severe endometriosis, right ovarian endometriosis, adenomyosis  
Both surgical menopause  
oestrogen and progestogen’ [3 months, 1 year]  
(2) Oestrogen patch [19 months]  

| HRT type | Dosages and regimens associated with recurrent endometriosis (n = 17 patients) |
|----------|----------------------------------------------------------------------------------|
| Oestrogen-only 1: Premarin 2.5 mg/day (Goh and Hall, 2007) |
| 2: Premarin 2.5 mg/day (Goh and Hall, 2005) |
| 3: Oestrogen patch 0.05 mg once a week (Ray et al., 2005) |
| 4: Oestrogen patch 0.05 mg twice a week (Ray et al., 2005) |
| 5: Oestradiol implant (Ray et al., 2005) |
| 6: Oestradiol implant 1.25 mg/day (Goh and Hall, 2005) |
| 7: Oestradiol implant 100 μg/day for 5 years, followed by 100 μg/day for 2 years (Goh and Hall, 2005) |
| 8: Oestradiol implant 1 mg/day (Goh and Hall, 2005) |
| 9: Oestradiol implant (Taylor et al., 2005) |
| 10: Oestradiol + cyproterone [3 months] |
| 11: Oestradiol + norethisterone [7 years] |
| 12: Oestradiol + oestradiol implants, followed by oestradiol patches [Not specified, but patient stopped HRT 12 months prior to presentation] |
| 13: Conjugated equine oestrogens 50 μg, norethisterone 100 μg/daily (Goh and Hall, 2005) |
| 14: Conjugated equine oestrogens 62.5 μg, norethisterone 150 μg cyclically (Giarenis et al., 2007) |
| 15: Oestradiol + progesterone [Joseph et al., 1994] |
| 16: Oestradiol + progesterone [Joseph et al., 1994] |
| 17: Oestradiol and cyproterone (Chahine et al., 2007) |

TAH, total abdominal hysterectomy; SO, salpingo-oophorectomy; ERT, oestrogen-replacement therapy. Surgical menopause refers to procedures involving bilateral oophorectomy.
therapy involving Depo-Provera (Skor et al., 1977), Danazol (Manyonda et al., 1989) and Tibolone (Taylor et al., 1999; Mattar et al., 2008). Three patients resumed HRT after surgery (Goh and Hall, 1992; Taylor et al., 1999; Badawy et al., 2004), two of whom were prescribed oestrogen-only formulations (Goh and Hall, 1992; Badawy et al., 2004).

Outcomes were generally favourable, although reporting bias may have contributed to this finding. All patients with reported follow-up (range: immediate postoperative checks to 2 years post treatment) experienced symptom regression with no relapses in the follow-up period (Skor et al., 1977; Stewart and Ireland, 1977; Kapadia et al., 1984; Manyonda et al., 1989; Goh and Hall, 1992; Joseph et al., 1994; Taylor et al., 1999; Chahine et al., 2007; Giarenis et al., 2009).

Malignant transformation (25 patients)

Twenty case reports and series of malignant transformation of endometriotic foci in postmenopausal women with a history of endometriosis on HRT were identified. This included a total of 25 patients between the ages of 38 and 75 years old (mean: 56 years) (Table IV). An additional study by Leiserowitz and colleagues (2003) (Leiserowitz et al., 2003) detailing the malignant transformation of endometriosis in six postmenopausal women on oestrogen-only HRT (mean duration: 23.4 years) is included in Table IV, but will be discussed separately.

Severity of prior endometriosis

About 13 patients had medical histories that noted endometriosis in more than one site (Brooks and Wheeler, 1977; Duun et al., 1993; Abu et al., 1997; Powell et al., 2001; Jones et al., 2002; Petersen et al., 2002; Soliman and Evans, 2004; Milam et al., 2006; Noel et al., 2006; Efthymiou, 2009; Karanjgaokar et al., 2009), and 13 patients had histories of ovarian endometriosis (Brooks and Wheeler, 1977; Duun et al., 1993; Abu et al., 1997; Jimenez et al., 2000; Powell et al., 2001; Montamedi, 2002; Petersen et al., 2002; Soliman and Evans, 2004; Milam et al., 2006; Efthymiou, 2009; Karanjgaokar et al., 2009). Some histories specified ‘severe endometriosis’ (n = 4) (Duan et al., 1993; Abu et al., 1997; Taylor et al., 1999; Efthymiou, 2009), while others reported ‘extensive endometriosis’ (n = 4) (Reimnitz et al., 1988; Soliman and Evans, 2004; Noel et al., 2006). Some histories included comorbidities such as leiomyomas (n = 6) (Brooks and Wheeler, 1977; Reimnitz et al., 1988; Powell et al., 2001; Areia et al., 2004; Soliman and Evans, 2004; Kawate et al., 2005) and adenomyosis (n = 5) (Brooks and Wheeler, 1977; Abu et al., 1997; Powell et al., 2001; Noel et al., 2006; Karanjgaokar et al., 2009). Patients typically underwent surgical menopause (n = 22) (Brooks and Wheeler, 1977; Reimnitz et al., 1988; Duan et al., 1993; Abu et al., 1997; Taylor et al., 1999; Jimenez et al., 2000; Powell et al., 2001; Jones et al., 2002; Montamedi, 2002; Petersen et al., 2002; Areia et al., 2004; Soliman and Evans, 2004; Kawate et al., 2005; Milam et al., 2006; Noel et al., 2006; Al-Talib et al., 2008; Efthymiou, 2009; Karanjgaokar et al., 2009). Two additional patients underwent oophorectomy at ages 60 (Klug et al., 1987) and 57 (Soliman and Evans, 2004) respectively; however, it was unclear in these two cases whether the patients had already naturally transitioned to menopause.

Menopausal hormonal preparations

HRT commonly consisted of unopposed oestrogens (n = 19) (Brooks and Wheeler, 1977; Klug et al., 1987; Reimnitz et al., 1988; Duun et al., 1993; Abu et al., 1997; Taylor et al., 1999; Jimenez et al., 2000; Powell et al., 2001; Jones et al., 2002; Montamedi, 2002; Petersen et al., 2002; Areia et al., 2004; Soliman and Evans, 2004; Kawate et al., 2005; Milam et al., 2006; Noel et al., 2006; Al-Talib et al., 2008; Efthymiou, 2009; Karanjgaokar et al., 2009). Other historical types included adenosarcoma (n = 2) (Milam et al., 2006; Karanjgaokar et al., 2009), clear cell carcinoma (n = 1) (Brooks and Wheeler, 1977), Mullerian carcinosarcoma (n = 1) (Noel et al., 2006), Malignant transformation of endometriotic foci was commonly diagnosed using Sampson’s (Sampson, 1925) and Scott’s (Scott, 1953) criteria. Endometrioid adenocarcinoma was by far the most commonly diagnosed HRT-associated malignancy in patients with a history of endometriosis (n = 18) (Klug et al., 1987; Reimnitz et al., 1988; Duan et al., 1993; Abu et al., 1997; Taylor et al., 1999; Jones et al., 2002; Montamedi, 2002; Petersen et al., 2002; Areia et al., 2004; Soliman and Evans, 2004; Kawate et al., 2005; Al-Talib et al., 2008; Chung et al., 2008; Efthymiou, 2009; Karanjgaokar et al., 2009). Other presentations included uterine malignancies such as adenosarcoma (n = 7) (Reimnitz et al., 1988; Karanjgaokar et al., 2009).
Table IV  Case reports and series reporting malignant transformation of endometriotic foci after HRT in women with a history of endometriosis.

| Author, date (N patients) | Patient age (years) | Presenting symptoms | Medical history and menopause | HRT [duration] | Diagnosis | Treatment [follow-up: patient status] |
|--------------------------|---------------------|---------------------|-----------------------------|----------------|-----------|-------------------------------------|
| Brooks and Wheeler (1977) (N = 1) | 48 | Mild right-sided lower abdominal pain, urinary frequency, constipation for 2 months [No] | Pelvic endometriosis, left ovarian endometriosis, adenomyosis, leiomyomas, Surgical menopause | Oestrogen-only HRT | Clear cell carcinoma arising in endometriosis of the retroperitoneum | Surgery + radiation [22 months: no evidence of disease] |
| Klug et al. (1987) (N = 1) | 66 | Light vaginal bleeding [No] | Genital endometriosis | Oestrogen-only HRT | Endometrioid carcinoma arising in an endometriotic lesion of the cul-de-sac | Surgery [Unclear] |
| Reimnitz et al. (1988) (N = 2) | (1) 58 (2) 47 | (1) Vaginal bleeding and left flank pain [Yes] (2) Nausea, vomiting, fever and flank pain [Yes] | (1) Extensive endometriosis and leiomyomata, Surgical menopause | Both oestrogen-only HRT (1) [12 years] (2) [4 years] | (1) Extra-ovarian endometrioid carcinoma arising in foci of endometriosis (2) Adenocarcinoma + adenosquamous carcinoma arising in foci of endometriosis 3 months later | (1) Surgery + progestin therapy [60 months: no evidence of disease] (2) Surgery + progestin therapy + radiation + chemotherapy [11 months: patient deceased] |
| Duun et al. (1993) (N = 1) | 62 | Pelvic mass [No] | Severe endometriosis (both ovaries and extensions deep into the rectovaginal septum) | Oestrogen-only HRT Intramuscular oestrogen injections [20 years] | Endometrioid adenocarcinoma (extraluminal rectosigmoid tumour 10 cm in diameter and closely adherent to the bladder) | Surgery + radiation [6 weeks: patient deceased] |
| Abu et al. (1997) (N = 1) | 38 | Intermittent vaginal bleeding of 8 weeks duration, ulcerated area over vaginal vault, polyp-like lesion on vaginal vault found 4 weeks later [No] | Severe endometriosis involving both ovaries, adenomyosis of the uterus, chronic cervicitis, Surgical menopause | Oestrogen-only and combined HRT Ethinyloestrodiol tablets [Not specified] Levonorgestrel/ethinyloestrodiol tablets [Not specified] Oestradiol implants [Not specified] | Endometrial adenocarcinoma arising from an endometriotic focus | Neoadjuvant progestin therapy + surgery + radiation [Not specified] |
| Taylor et al. (1999) (N = 1) | 42 | Massive ascites, 6L drained [No] | Severe endometriosis | Oestrogen-only HRT Oestradiol implants [7 years] | Endometriot adenocarcinoma | Surgery + chemotherapy [24 months: no evidence of disease] |
| Jimenez et al. (2000) (N = 1) | 48 | Right flank discomfort [Yes] | Endometriotic ovarian cyst | Oestrogen-only HRT Conjugated oestrogen tablets [5 years] | Adenosquamous endometrioid carcinoma arising from disseminated pelvic endometriosis | Surgery [Not specified] |
| Powell et al. (2001) (N = 1) | 56 | Lower abdominal pain, dyspareunia, pain with bowel movements, hirsutism [Yes] | Extensive pelvic adhesions, peritoneal endometriosis, left ovarian endometrioma, adenomyosis, multiple leiomyomas, Surgical menopause | Oestrogen-only HRT and combined HRT Conjugated oestrogen tablets [10 years] Medroxyprogesterone tablets [3 years] | Androgen-producing endometrioid tumour of low malignant potential (borderline tumour) arising in endometriosis in the rectovaginal septum | Surgery + chemotherapy + progestin therapy [9 months: no evidence of disease] |

Continued
| Author, date (# patients) | Patient age (years) | Presenting symptoms [ureter involvement] | Medical history and menopause | HRT [duration] | Diagnosis | Treatment [follow-up: patient status] |
|---------------------------|----------------------|------------------------------------------|--------------------------------|----------------|-----------|-------------------------------------|
| Jones et al. (2002)       | 52                   | Rectal bleeding and polyp arising from sigmoid colon [Yes] | Deeply infiltrating rectovaginal endometriosis Surgical menopause | Oestrogen-only HRT Oestradiol implants [12 years] | Well-differentiated endometrial adenocarcinoma arising from endometriosis of the rectosigmoid colon | Surgery [9 months: no evidence of disease] |
| Montamedi (2002)          | 57                   | Right lower-quadrant pain, recurrent macroscopic haematuria and weight loss of 8 kg in 3 months [Yes] | Uterine fibroids and right-sided endometrioma Surgical menopause (left ovary and fallopian tube left intact) | Oestrogen-only HRT Oestradiol ['many years'] | Tubulopapillary endometrioid adenocarcinoma involving blood vessels | Surgery + radiation [18 months: no evidence of disease] |
| Petersen et al. (2002)    | (1) 61  (2) 57       | (1) Diarrhoea, right buttock pain, rectal mass [No] (2) Lower abdominal pain, rectal mass [No] | (1) Endometriosis Surgical menopause (2) Endometriotic foci on uterus, haemorrhagic endometriotic ovarian cyst Surgical menopause | (1) Oestrogen-only HRT [5 years] (2) HRT [8 years] | (1) Poorly differentiated endometrioid adenocarcinoma of the large intestine arising in colorectal endometriosis (2) Variously differentiated endometrioid adenocarcinoma | (1) Surgery [28 months: no evidence of disease] (2) Surgery [18 months: no evidence of disease] |
| Leiserowitz et al. (2003)* | 54.9 (mean)          | Not reported | Not reported Surgical menopause (n = 8) | Oestrogen-only HRT (n = 6) [23.4 years (mean), 10–32 years (range)] | Endometrioid (n = 5) Adenosquamous (n = 2) Papillary adenocarcinoma (n = 1) Adenocarcinoma not otherwise specified (n = 2) | Surgery, chemotherapy, radiation [26 months (mean): 70% survival] |
| Soliman and Evans (2004)  | (1) 60  (2) 51       | (1) Heavy, painless vaginal bleeding, palpable fixed mass, polypoid necrotic lesion [Yes] (2) Painless mass in the right side of abdomen and several episodes of vaginal bleeding [Yes] | 1) Pelvic endometriosis, microinvasive squamous carcinoma of the cervix, leiomyoma Menopause not specified (surgical menopause at age 57) 2) Extensive endometriosis involving the uterosacral ligaments, endometriotic right ovarian cyst Surgical menopause (left ovary and Fallopian tube left intact) | 1) Oestrogen-only HRT Conjugated equine oestrogen tablets [3 years] 2) Combined HRT Oestrogen and testosterone implants [10 years] | (1) Moderately differentiated endometrial adenocarcinoma (2) Endometrioid adenocarcinoma arising in an endometriotic cyst within the vaginal vault | (1) Surgery and radiation [48 months: no evidence of disease] (2) Surgery [24 months: no further tumour growth] |
| Areia et al. (2004)       | 53                   | Abnormal vaginal bleeding for 2 months [Yes] | Leiomyomata, endometrioid foci especially in Fallopian tubes Surgical menopause | Oestrogen-only HRT Oestradiol [6 years] | Endometrioid adenocarcinoma affecting the vagina, bladder and rectum | Surgery + chemotherapy [6 months: no evidence of disease] |
| Kawate et al. (2005)      | 62                   | Abdominal mass [No] | Infiltrating pelvic endometriosis, leiomyoma Surgical menopause | Oestrogen-only HRT Conjugated oestrogen tablets [14 years] | Endometrioid adenocarcinoma arising from endometriosis of the mesocolon | Surgery + chemotherapy [28 months: no evidence of disease] |
| Noel et al. (2006)        | 75                   | Chronic abdominal pain for 2 months, left pyelonephritis [Yes] | Extensive endometriosis and adenomyosis Surgical menopause | Oestrogen-only HRT Super concentrated phytoestrogen supplements [5 years] | Ureteral malignant Mullerian carcinosarcoma in a context of florid endometriosis | Surgery + aromatase inhibitor [3 months: no evidence of disease] |
| Milam et al. (2006)       | 47                   | Persistent and enlarging right groin mass, right lower-quadrant tenderness [No] | Recurrent endometriosis, left and right endometriomas Surgical menopause | Oestrogen-only HRT Oestradiol tablets [16 years] | Adenosarcoma arising in endometriosis | Surgery [12 months: no evidence of disease] |
| Study | N | Symptoms | Menopause | HRT | Diagnosis | Treatment |
|-------|---|----------|-----------|-----|-----------|-----------|
| Al-Taib et al. (2008) | 1 | Left-sided pelvic mass, shortness of breath [No] | Endometriosis and multiple large fibroids | Oestrogen-only HRT [13 years] | Metastatic endometrioid adenocarcinoma | Chemotherapy [24 months: patient is alive and well] |
| Chung et al. (2008) | 1 | Abdominal/pelvic pain and mass, alteration of general state, 10 kg weight loss, constipation, dysuria [Yes] | Never had endometriosis-specified pain, but unclear whether patient had endometriosis | Combined HRT Oestradiol and medroxyprogesterone acetate [11 years] | Extrapelvic endometrioid carcinoma in the vesico-uterine pouch arising from endometriosis | Surgery + chemotherapy + radiation [8 months: patient deceased] |
| Efthymiou (2009) | 1 | 8-week history of constipation, tenesmus, 7 kg weight loss [No] | Severe ovarian endometriosis and in floor of pelvis | Combined HRT Oestradiol and testosterone implant [13 years] | Well-demarcated, cystic, endometrioid adenocarcinoma (endometriosis-associated intestinal tumour) | Surgery [Not specified] |
| Karanjgaokar et al. (2009) | 3 | (1) Intermittent right-sided abdominal pain for 4 years [Yes] (2) Recent onset of discomfort in her right iliac fossa [No] (3) Cramp-like discomfort in the abdomen and thighs and postmenopausal bleeding [No] | 1) Ovarian endometriosis and adenomyosis 2) Widespread endometriosis in the ovary, uterine serosa and bowel 3) Endometriosis and left ovarian endometrioma | 1) Oestrogen-only HRT Oestrogen implants [14 years, discontinued 8 years before presentation] 2) Combined HRT Oestradiol and testosterone implants [12 years, discontinued 4 years before presentation] 3) Combined HRT Oestrogen and testosterone implants [9 years] | (1) Adenosarcoma with heterologous leiomyosarcomatous element and moderately differentiated endometrioid adenocarcinoma (2) Endometrioid adenocarcinoma (3) High grade endometrial stromal sarcoma arising in residual foci of endometriosis and infiltrating the bowel | (1) Surgery + aromatase inhibitor + chemotherapy (2) Surgery + chemotherapy (3) Surgery + chemotherapy [All cases were still being treated at the time of publication] |

TAH/BSO, total abdominal hysterectomy and bilateral salpingo-oophorectomy.

*Article describes a total of 27 women with endometriosis-related malignancy; however, it is unclear how many of these women were postmenopausal. A subgroup of women with extra-ovarian disease (n = 10) included eight women with a history of hysterectomy and BSO, and one further woman who was taking unopposed oestrogens (therefore was presumably menopausal). For the purposes of this analysis, only these 10 women are described.*
endometrial stromal sarcoma \((n = 1)\) (Karanigaokar et al., 2009) and an androgen-producing endometrial borderline tumour \((n = 1)\) (Powell et al., 2001). One interesting study reported an adenocarcinoma followed by an adenosquamous carcinoma arising in endometriotic foci 3 months later (Reimnitz et al., 1988).

Treatments varied based on histological type, grade and stage of the tumour. In only one case it was decided to forego surgical management and treat solely with chemotherapy (Al-Talib et al., 2008). In this case, the decision to initiate chemotherapy instead of surgery was based on her previous surgical history (two ileostomies) and poor prognosis due to advanced disease.

Adjuvant or neoadjuvant treatments in the form of chemotherapy \((n = 9)\) (Reimnitz et al., 1988; Taylor et al., 1999; Powell et al., 2001; Areia et al., 2004; Kawate et al., 2005; Chung et al., 2008; Karanigaokar et al., 2009), radiation \((n = 7)\) (Brooks and Wheeler, 1977; Reimnitz et al., 1988; Duun et al., 1993; Abu et al., 1997; Montamedi, 2002; Soliman and Evans, 2004; Chung et al., 2008) or progestin therapy \((n = 4)\) (Reimnitz et al., 1988; Abu et al., 1997; Powell et al., 2001) were frequently initiated. Mean follow-up was 19.4 months (range: 6 weeks to 5 years). Outcomes were generally favourable with no evidence of disease in 13 patients at follow-up (Brooks and Wheeler, 1977; Reimnitz et al., 1988; Taylor et al., 1999; Powell et al., 2001; Jones et al., 2002; Montamedi, 2002; Petersen et al., 2002; Areia et al., 2004; Soliman and Evans, 2004; Kawate et al., 2005; Milam et al., 2006; Noel et al., 2006). The patient treated solely with chemotherapy was alive and well at 2 years after presentation (Al-Talib et al., 2008).

Mortality

Although the majority of patients responded to treatment and were cured of their malignancy, three of the 25 patients diagnosed with an endometriosis-associated malignancy died as a result of their disease (Reimnitz et al., 1988; Duun et al., 1993; Chung et al., 2008). Reimnitz et al. (1988) reported the case of a 47-year-old woman with a history of extensive pelvic endometriosis. She was on conjugated oestrogens (Premarin) 0.625 mg for 5 days every week for 4 years. She was initially diagnosed with a grade two adenocarcinoma arising from an endometriotic focus and obstructing the left ureter. Subsequently she was also diagnosed with moderately differentiated adenosquamous carcinoma arising from endometriotic foci. The patient was treated with cisplatinum and cyclophosphamide chemotherapy, but died after 11 months. In the case reported by Duun et al. (1993), the patient was a 62-year-old woman with a history of severe endometriosis involving both ovaries and the rectovaginal septum. She had received intramuscular oestrogen injections for 20 years following a hysterectomy and bilateral oophorectomy. After 3 years with no treatment, she resumed another hormone substitution regimen (not specified) for hot flushes. Within a year of commencing this hormonal substitution, the patient presented with a pelvic mass diagnosed as endometrioid adenocarcinoma. About 6 weeks after tumour excision, recurrence was diagnosed and the patient died despite radiotherapy. Chung et al. (2008) reported the case of a 66-year-old woman who presented with abdominal/pelvic pain and mass, alteration of general state, 10 kg weight loss, constipation and dysuria. She had used combined HRT (oestradiol and medroxyprogesterone acetate) for 11 years. After being diagnosed with extravaginal endometrioid carcinoma in the vesico-uterine pouch arising from endometriosis, she was treated with surgery, chemotherapy and radiation. The patient was deceased 8 months later.

One unique case series by Leiserowitz et al. (2003) identified by our search reported on larger numbers of women and thus is presented separately. They describe the management of 27 women with endometriosis-related malignancy, identified during a 7-year period (by their presentation to one of the authors, and review of pathology records). The authors include all women with endometriosis-related malignancy, rather than exclusively postmenopausal women. However, it is clear from the article that a number of participants were postmenopausal. In particular, 10 women were identified with extragonadal (non-ovarian) malignancy, and 9 of these were clearly menopausal (with either a medical history of hysterectomy/BSO, or reported as using HRT). Of these 10 women, their malignancies were histologically described as endometrioid \((n = 5)\), adenosquamous \((n = 2)\), papillary adenocarcinoma \((n = 1)\) or adenocarcinomas not otherwise specified \((n = 2)\). Within this group, six women had taken unopposed oestrogen therapy for a mean duration of 23.4 years (range 10–32 years). The authors therefore suggest that unopposed oestrogen use could be a risk factor for endometriosis-associated malignancy, especially of non-ovarian location. Treatments included surgery, chemotherapy and radiation with a 70% reported survival at follow-up (mean: 26.3 months).

### Observational studies and clinical trials (6 studies)

Only six observational studies and clinical trials were identified by our search, highlighting the paucity of higher-level evidence in this area. These studies aimed to cover a variety of clinical questions, and the evidence for these is summarized below and in Table V. All assessed recurrence of endometriosis as their primary outcome.

### Should HRT be given to women with previous endometriosis?

Given the concerns of possible disease reactivation or malignant transformation of endometriotic foci, it is reasonable to consider whether treatment with HRT is justifiable in this group of women. However, in a field dominated by case reports and series, it is challenging to obtain information on risk. Our search identified a single RCT and two cohort studies that give some insight regarding the risk of HRT in this cohort of women. All three studies were assessed as very low quality by GRADE criteria (Guyatt et al., 2011).

The only RCT in this area was a single centre study from Spain, including a total of 172 women (Matorras et al., 2002). All participants had a history of endometriosis and underwent BSO. Women were randomly allocated to treatment with combined HRT (50 μg oestradiol daily administered via patches and oral micronized progesterone for 14 days out of every 30 days) or no treatment. Participants were aware of their treatment allocation, although the clinician assessing them was not. In the treatment group, HRT was started 4 weeks following surgery. All women were followed up every 6 months with a clinical review, vaginal ultrasound and hormone measurements. Recurrence of endometriosis was identified either through histological confirmation, or by clinical findings (pelvic pain and/or pelvic mass) in association with pelvic ultrasound images suggestive of endometriosis. The overall absolute recurrence rate for
Table V Quality assessment of observational and clinical trials assessing risk of endometriosis recurrence after HRT.

| Quality assessment | Study design          | Risk of bias | Inconsistency | Indirectness | Imprecision | Other considerations | Intervention | Control | Effect | Evidence quality |
|--------------------|-----------------------|--------------|---------------|--------------|-------------|----------------------|--------------|---------|--------|------------------|
| **Comparison of HRT with no HRT** | Matorras et al. (2002) | Randomized trial | Serious<sup>a</sup> | Not serious | Not serious | Very serious<sup>b</sup> | None | HRT | 4/115 (3.5%) | RR 4.50 (0.25 to 82.17)<sup>c</sup> VERY LOW |
|                    | Rattanachaiyanont et al. (2003) | Observational study | Very serious<sup>d</sup> | Not serious | Not serious | Very serious<sup>b</sup> | None | HRT | 4/90 (4.4%) | RR 1.78 (0.10 to 31.64)<sup>c</sup> VERY LOW |
|                    | Acien et al. (2013) | Observational study | Serious<sup>e</sup> | Not serious | Not serious | Not applicable<sup>f</sup> | None | No treatment | 0/11 (0%) | Not calculable<sup>f</sup> VERY LOW |
| **Comparison of delayed HRT with immediate HRT** | Hickman et al. (1998) | Observational study | Not serious | Not serious | Not serious | None | HRT | 7/35 (20.0%) | HR 5.74 (1.31 to 25.23)<sup>b</sup> LOW |
|                    | Arumugam and Damodaran (1998) | Observational study | Very serious<sup>d</sup> | Not serious | Not serious | Not applicable<sup>f</sup> | None | Immediate HRT | 4/60 (6.7%) | Not calculable<sup>f</sup> VERY LOW |
| **Comparison of HRT with tibolone** | Fedele et al. (1999) | Randomized trial | Serious<sup>i</sup> | Not serious | Not serious | Very serious<sup>b</sup> | None | HRT | 4/10 (40.0%) | RR 4.40 (0.59 to 33.07)<sup>c</sup> VERY LOW |
| **Comparison of oestrogen-only HRT with combined HRT** | Rattanachaiyanont et al. (2003) | Observational study | Very serious<sup>d</sup> | Not serious | Not serious | Very serious<sup>b</sup> | None | Immediate HRT (continuous and cyclical) | 0/40 (0.0%) | RR 7.24 (0.40 to 130.54)<sup>c</sup> VERY LOW |

CI, confidence interval; HR, hazard ratio; HRT, hormone replacement therapy; RR, risk ratio.

<sup>a</sup>High risk of performance bias—single blinded study, with physician unaware of treatment allocation, but with access to hormone results (which would have indicated treatment with HRT or not). High risk of detection bias, as assessment for recurrence was only carried out if the clinician felt this was warranted, which may have been influenced by the participant (who was not blind to treatment allocation).

<sup>b</sup>Very wide CI for RR.

<sup>c</sup>RR calculated by the authors using Review Manager (RevMan) [Computer program]. Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014.

<sup>d</sup>High risk of selection bias as unclear why women were allocated to different HRT regimens (or no HRT). High risk of detection bias, as researchers would have been aware of the woman’s HRT status when assessing presence of recurrence (by reviewing medical records).

<sup>e</sup>Risk of detection bias, as criteria for designating recurrence are not clearly stated.

<sup>f</sup>Not applicable as odds ratio and CI cannot be calculated.

<sup>g</sup>No events in either group, therefore odds ratio not calculable.

<sup>h</sup>HR adjusted for stage of endometriosis, age at time of hysterectomy and postoperative adjunct medroxyprogesterone therapy.

<sup>i</sup>High risk of selection bias (unclear why some women started HRT after 3 months and some after 5 months), and high risk of detection bias (recurrence was only based on CA 125 levels).

<sup>j</sup>No description of blinding for the trial, and no scoring system is reported for pain, therefore risk of detection bias.
endometriosis in this study was low at 2.3% (4/172). However, all women who experienced recurrence of endometriosis had been assigned to the HRT treatment arm (recurrence in 3.5% (4/115) of women compared to 0% (0/57) of women in the no treatment arm). The authors also suggested that the presence of residual endometrial tissue may be a possible risk factor for disease recurrence. In this cohort, the recurrence rate was 22.2% in women who had either a subtotal hysterectomy or BSO alone (2 out of 9 women). In contrast, the rate was only 1.9% (2 out of 106 women) in those who had total hysterectomy and BSO. The authors further suggest that a greater burden of disease may increase the risk of recurrence, as shown by an increased recurrence risk for women who had peritoneal involvement of greater than 3 cm, and a non-significant trend to increased recurrence with more advanced stages of endometriosis. The authors rightly noted that their study was underpowered to detect a statistically significant change in recurrence rates between the two groups of women. However, the study raises interesting possibilities for further research into the effect of disease stage and extent on recurrence rates.

One observational study included women who took postoperative HRT (of different regimens) and those who did not (Rattanachaiyanont et al., 2003). In this retrospective, single centre cohort, the authors identified 107 women who had undergone hysterectomy and BSO for treatment of endometriosis. Women were treated with a variety of HRT regimens (total n = 90, taking unopposed oestrogen, continuous combined HRT, or cyclic HRT) or no treatment (n = 17). Recurrence was only identified in four women and all were receiving HRT, specifically unopposed oestrogen therapy. Three women had recurrent pain, and one woman had a vaginal nodule, confirmed as endometriosis on histology.

One further observational study reported on outcomes of women with deep infiltrating endometriosis and colorectal or rectovaginal disease, who underwent surgery without bowel resection (Acien et al., 2013). This retrospective comparative cohort study was conducted in Spain and included women who were operated on at one of two hospitals. Of 42 patients, 19 had a hysterectomy and BSO, whilst the remainder had conservative surgery. Of the 19 women who underwent surgical menopause, 11 were subsequently treated with HRT, comprising 1–2 years of combined oestrogen/progesterone, followed by low dose oestrogen-only HRT or tibolone, continued indefinitely. The remaining 8 women did not receive HRT. The mean follow-up was 4.3 years (standard deviation 4.5, range 1–18). During this time, no women from either group were diagnosed with recurrence of endometriosis.

**Should HRT be given immediately following surgical menopause?**

Further questions arise for women who undergo surgical menopause. If small deposits of endometriotic tissue remain following surgery, these may be triggered to proliferate by exogenous oestrogens given as HRT and increase the risk of recurrence or malignant transformation. Therefore, there may be a theoretical benefit in delaying the start of HRT, by allowing time for residual endometriotic tissue to regress before commencing exogenous oestrogen. Two retrieved articles, a retrospective cohort study (Hickman et al., 1998) (GRADE: low quality) and non-comparative cohort (Arumugam and Damodaran, 1998) (GRADE: very low quality), attempted to investigate this question.

The retrospective cohort study (Hickman et al., 1998) included women who underwent TAH with BSO, identified from the medical records of a single institution during a period of 12 years (1979–1991). Two groups of women were identified: those who commenced HRT within 6 weeks of their surgery (n = 60) and those who delayed starting HRT for at least 6 weeks (n = 35, mean time to starting HRT 71.1 weeks, range 7–520 weeks). Women who did not receive HRT were excluded. Information on symptom recurrence was obtained through the medical records or telephone follow-up, but a precise definition of recurrence was not reported. The mean duration of follow-up was 4.5 years. In unadjusted analyses, 4/60 (6.7%) women who began HRT immediately had recurrent pain, compared to 7/35 (20%) women who began HRT later on. Of note, in their adjusted analyses, in which endometriosis stage, age and post-operative adjunct medroxyprogesterone therapy were considered, starting oestro-gen-replacement therapy (ERT) more than 6 weeks after surgical menopause had a hazard ratio of 5.7 for pain recurrence (95% CI: 1.3, 25.2). The authors therefore conclude that there is no increase in the risk of recurrence for women who commenced ERT immediately, as compared to those who delayed treatment.

A non-comparative cohort study (Arumugam and Damodaran, 1998) prospectively followed 13 women at one institution in Malaysia undergoing TAH and BSO for moderate or severe endometriosis. Patients were premenopausal at recruitment and had their endometriosis activity assessed by blood CA 125 levels taken pre-operatively and post-operatively (monthly). Eight patients received conjugated oestrogens in the form of Premarin (oral dose of 0.625 mg/day) starting 5 months post surgery, and five patients received oestrogens 3 months post surgery. Preoperative CA 125 levels were high in all 13 patients and declined to normal post surgery. Levels did not rise during the 6-month follow-up period and patients remained well and asymptomatic.

**What menopausal treatments are most appropriate for women with previous endometriosis?**

If a woman with a history of endometriosis does decide to opt for HRT, then the next decision must be to choose the most suitable preparation. Again, there is limited high-quality evidence on which to base this decision. Two studies, retrieved by our search, provide some insight into this question. The first was a RCT (Fedele et al., 1999) comparing HRT using transdermal oestradiol with tibolone, and the second was an observational study (Rattanachaiyanont et al., 2003) comparing oestrogen-only HRT with combined HRT. Both were assessed as very low quality using the GRADE system.

The RCT (Fedele et al., 1999) compared HRT (n = 10, transdermal oestradiol 50 mg twice weekly plus cyclic medroxyprogesterone acetate 10 mg daily for women with a uterus) and tibolone (n = 11, 2.5 mg orally once a day) in women with residual endometriosis after bilateral oophorectomy. Patients were randomized into one of the two treatment groups and followed for 1 year. Four patients in the oestradiol group experienced moderate pelvic pain during treatment...
compared to only one patient in the tibolone group. Furthermore, one patient in the HRT group discontinued treatment at 8 months due to the development of dyspareunia and post-coital bleeding from a vaginal mucosal endometriotic deposit. The authors concluded that tibolone may be a safer alternative for postmenopausal women with residual endometriosis, although note that their trial was very small.

The observational cohort study (Rattanachaiyanont et al., 2003) attempted to compare various HRT regimens in women who had undergone hysterectomy and BSO for endometriosis. The majority of women (n = 50) were treated with unopposed oral oestrogen. Others were prescribed either continuous combined HRT (n = 24) or cyclical HRT (n = 16). Women received either conjugated equine oestrogens or oestradiol. Finally, a small group of women received no HRT (n = 17) and were viewed as controls. Women were followed up for a mean duration of 3.5 years (range 0.5–18 years). Although there were no statistically significant differences between the groups, the only episodes of recurrence (n = 4) were found in the oestrogen-only group. One woman who suffered with recurrent symptoms whilst taking oestrogen-only HRT also had relief of her symptoms when changing to a combined preparation. The authors conclude that HRT, particularly combined oestrogen and progestin regimens, is safe for postmenopausal women with underlying endometriosis.

Discussion

In response to concerns regarding an increased risk of breast cancer raised by the Women’s Health Initiative (Rossouw et al., 2002) and the Million Women Study (Collaborators, 2003), HRT usage substantially decreased (Hersch et al., 2004). Nevertheless, millions of women continue to rely on hormonal preparations for menopausal symptom relief and HRT remains the most effective treatment for menopausal vasomotor symptoms and vulvar and vaginal atrophy (Schmidt, 2012). However, amongst women with a history of endometriosis, HRT may entail additional risks, and to date there are no high-quality evidence-based guidelines to guide clinical decisions.

The articles described here provide insight into the management of menopausal symptoms amongst women with a prior history of endometriosis. The case reports and series included in our review, while limited in their usefulness in assessing prevalence, indicate that recurrence of endometriosis and malignant transformations can occur in postmenopausal women. Observational studies and clinical trials have further investigated the contingent risks of different forms and timing of HRT treatments.

Recurrence

Endometriosis is not exclusively a premenopausal disease. About 13 case reports and series identified 17 cases of recurrent endometriosis in postmenopausal women taking some form of HRT. These cases included women who underwent natural and surgical menopause; however, the vast majority underwent surgical menopause, perhaps indicating more severe premenopausal disease. Similarly, Vignali and colleagues (2005) reported substantial 5-year endometriosis recurrence rates, albeit amongst premenopausal women, of 43.5% (pain) and 28% (clinical disease) for women treated with conservative surgery (preservation of the uterus and at least one ovary) (Vignali et al., 2005).

In the case reports, symptoms of postmenopausal endometriosis were similar to those reported in premenopausal endometriosis (Mounsey et al., 2006): abnormal bleeding and pain. There are few papers describing the presentation of chronic pelvic pain (CPP) in postmenopausal women specifically. From clinical experience, symptoms are not cyclical unless a cyclical HRT preparation is used; however, pain associated with bowel and bladder function is common in postmenopausal women with CPP. Dyspareunia, especially superficially, may be associated with atrophic tissues but may also present in women using HRT with well-oestrogenized tissues. Deep dyspareunia, the more pathognomonic form of painful intercourse associated with endometriosis, is rarely described. Future research should investigate the prevalence of this symptom and whether and to what extent dyspareunia (superficial or deep) may contribute to postmenopausal sexual behaviour. Perhaps the most important difference in clinical practice, however, is the need to investigate new onset pelvic pain in a postmenopausal woman, whilst guidance on the management of CPP in reproductive age women emphasizes the need to avoid over-investigation and thus over-medicalization of the symptom when no underlying cause has previously been found (Home Page. Map of Medicine Web site. http://www.mapofmedicine.com/). Findings from this review would suggest that investigation is needed when a postmenopausal woman is known to have had a previous diagnosis of endometriosis due to the added risk of malignant transformation.

The genitourinary system was the most common site of presentation, with many reports involving the ureter. This may represent the bias of case reports towards documenting more severe cases. Ureter involvement is a serious complication of endometriosis, capable of causing hydronephrosis and renal failure (Choi et al., 2015). It has been suggested that most cases of ureteral endometriosis in postmenopausal women are actually a result of delayed presentation with onset prior to menopause (Yohannes, 2003). However, due to a lack of clinically relevant biomarkers and sufficiently specific imaging techniques, the onset of endometriosis remains unclear (May et al., 2010; Dunselman et al., 2014).

Prognosis was generally favourable after excision of endometriotic tissue. Randomized controlled trials corroborate these findings, reporting decreased pain and symptoms after laparoscopic surgery for endometriosis, although these trials did not specifically investigate ureteric surgery (Duffy et al., 2014).

In three observational studies and one randomized clinical trial (Amugum and Damodaran, 1998; Matorras et al., 2002; Rattanachaiyanont et al., 2003; Acién et al., 2013), there appeared to be a small association between HRT and endometriosis recurrence, but there were no statistically significant differences between treatment and control groups. The current literature assessing risks of HRT in women with a history of endometriosis are uncertain, due to paucity of sufficiently large, high-quality studies. Current guidelines, consensus statements and recommendations acknowledge this deficit, but continue to emphasize the benefits of HRT over the undefined risks for severely symptomatic women (Al Kadri et al., 2009; Johnson and Hummelshoj, 2013; Dunselman et al., 2014). However, many women with endometriosis who undergo surgical menopause are given hormonal replacement therapy as a prophylaxis...
before the development of menopausal symptoms. For these women, clinicians must balance the benefits to bone (Cauley et al., 2003) and cardiovascular health (Rossouw et al., 2007), particularly for younger patients, against the potential risks of recurrence or malignancy.

It is important to note that recurrence is possible even in the absence of HRT. There are reports of endometriosis recurrence in women not on any hormonal treatment (Fujiu et al., 2010; Bhat et al., 2014). In these women, other risk factors such as hyperestrogenemia and obesity may play larger roles in the pathogenesis (Punnonen et al., 1980). Incomplete definitive surgery and residual ovarian remnants are also considered risk factors for the development of post-menopausal endometriosis (Dmowski et al., 1988). It remains to be confirmed whether a genetic predisposition together with environmental factors, medication, or fat distribution increase the risk of endometriosis after menopause, as has been shown for premenopausal women (Rahmioglu et al., 2015a,b).

Malignant transformation

Our search retrieved 20 case reports and series (25 patients) of malignant transformation of endometriotic foci following HRT. Of 25 patients, 22 had undergone surgical menopause, which was not surprising given that many women had a history of severe disease with comorbidities such as leiomyomas and adenomyosis. Unopposed oestrogens were implicated in 19 patients, with conjugated equine oestrogens implicated in eight patients and oestriadiol implants in four patients. Currently there are no data to indicate the absolute risk of malignant transformation in this group of women. It is likely that this is a rare outcome, but better data are urgently needed to enable women to make an informed decision about menopausal management. Fortunately, tumours arising from endometriosis are typically low grade and have a better prognosis (Heaps et al., 1990); only three deaths were reported in the literature identified by our search. Mortality was noted in the two case reports with patients who had histories of severe endometriosis and complicating factors, including increased age (Duun et al., 1993) or multiple malignancies (Reimnitz et al., 1988).

Considerations regarding type and timing of HRT

Adjusting the type and timing of the treatment plan may mitigate the potential risks of HRT highlighted by our case reports and series.

Type: oestrogen-only, combined or tibolone

Our review retrieved evidence on three main types of HRT: oestrogen-only, combined and tibolone.

A consistent theme among the case reports is the predominance of oestrogen-only HRT in women with recurrence or malignancy. The majority of case reports concerned women taking unopposed oestrogens, particularly conjugated equine oestrogens. This is not surprising given the strong association between unopposed oestrogens and endometrial cancer (Sogren et al., 2016). As a result, current recommendations favour continuous combined preparations instead of unopposed oestrogens for women with a history of endometriosis, but the evidence remains sparse (Soliman and Hillard, 2006; Oxholm et al., 2007). We identified a single observational study that addressed this issue, including only 90 women (Rattanachaianont et al., 2003). Although the only women who developed recurrent symptoms were those taking oestrogen-only HRT, the study was retrospective and unable to demonstrate statistically significant differences between the groups. The authors suggested that combined HRT preparations might be the most appropriate for women with endometriosis who are using HRT. Large, randomized trials or observational studies with appropriate statistical power are clearly needed to clarify this question. Further research is urgently needed given the increased risk of breast cancer associated with combined HRT, although it is mostly in the older age group, which has been attributed to progestins (Chlebowska et al., 2013).

Tibolone therapy has also been associated with recurrence of endometriosis (Sundar et al., 2007). One RCT included in our review considered the use of tibolone, as compared with combined HRT, but the results should be interpreted with caution given the small sample size (n = 21). Fedele and colleagues (1999) concluded that tibolone (which typically has an oestrogenic effect on climacteric symptoms and bone, yet a progestogenic effect on tissues) might be a safer alternative to traditional HRT in patients with residual endometriotic disease, but no statistically significant difference was seen between the groups.

Notably, one case report highlights the importance of asking patients about their use of supplements or complementary/alternative medication. Five-year use of a highly concentrated isoflavone supplement was associated with florid recurrence of endometriosis and ureteral malignant mullerian carcinosarcoma (Noel et al., 2006). This report raises further concerns over the use of phytooestrogens in postmenopausal women with a history of endometriosis (Crotoneo and Lamartiniere, 2001), despite some clinical and animal literature suggesting a reduced risk of endometriosis with dietary isoflavones (Tsuchiya et al., 2007; Yavuz et al., 2007). Given the high prevalence of supplement use, it is important to further explore the relationship between phytooestrogens and endometriosis.

Timing: initiation and duration

Data are also lacking on the optimal time to commence HRT following surgical menopause. We identified a retrospective study in this area, comparing immediate (within 6 weeks of surgery) to delayed (≥6 weeks following surgery) commencement of HRT (Hickman et al., 1998). Although the crude incidence of recurrence was not different between the groups, increased recurrence was noted for women who delayed starting HRT after adjusting for confounders (AFS score at time of surgery, age at hysterectomy and postoperative adjunctive use of medroxyprogesterone). The authors themselves note the strong likelihood of bias in this observational study; it is probable that deferring the start of HRT would have been recommended to women felt to be at higher risk of recurrent symptoms. Additionally, we retrieved a non-comparative cohort study (Arumugam and Damodaran, 1998), which prospectively followed eight women who received conjugated oestrogens in the form of oral daily Premarin 5 months post surgical menopause, and five women who received oestrogens 3 months post surgical menopause. Women from both groups remained well and asymptomatic at 6-month follow-ups, yet clearly a much longer follow-up duration is necessary to be able to accurately assess risk of recurrence. The authors of this study also did not specify any symptoms or provide additional detail on patient status, and thus the evidence provided by...
this study was assessed as very low quality. Randomized trials are clearly needed to avoid this risk of bias, and have the potential to answer this question robustly.

Our search retrieved no studies investigating the total time for which women with histories of endometriosis should be treated. This is unfortunate given that it takes time to acquire mutations in endometriotic tissue, and thus duration of HRT therapy may have a large impact on probability of malignancy. Our systematic review also retrieved case reports of malignant transformation 4 and 8 years after stopping HRT treatment (Karanjaokar et al., 2009), indicating that hormone replacement may either still have effects years after discontinuation or that the use of HRT is only one factor in malignant transformation of endometriosis.

**Conclusion**

Endometriosis is not exclusively a condition of the reproductive phase. Existing guidelines in this area emphasize the lack of evidence, but suggest that women should not be denied HRT treatment simply because of a history of endometriosis (Al Kadri et al., 2009; Dunselman et al., 2014). Our review indicates that women with a history of endometriosis should be carefully counselled about the possibility of disease recurrence after the menopause (Fig. 2). Although the absolute risk is unclear and likely to be low, women should be advised to seek help if they experience endometriosis-like symptoms, rather than suffer in silence. Furthermore, clinicians should adopt a cautious approach in cases of recurrence, keeping in mind the possibility of malignant transformation. For postmenopausal women with recurrent, treatment-resistant symptoms, consideration should be given to obtaining tissue for histology in order to exclude the possibility of malignancy, especially if other unusual or suspicious symptoms are present.

Although this review highlights potential risks of HRT, its substantial benefits should not be overlooked. In particular, the benefits may outweigh the costs of HRT for women with an early or surgical menopause. HRT has been shown to enhance cortical volumetric bone mineral density and compressive strength (Mikkola et al., 2011; Kuh et al., 2016). Additionally, studies have shown a reduced risk of coronary heart disease when hormonal therapy is administered to women with early natural or surgical menopause (Parker et al., 2009). Importantly, unilateral or bilateral oophorectomy prior to the onset of natural menopause is associated with an increased risk of
dementia and cognitive impairment (Rocca et al., 2007); however, these risks may be reduced if HRT is administered up until the average age of natural menopause (Rocca et al., 2014).

As with any woman commencing HRT, a full and frank discussion should be held about the risks and benefits of this treatment. Currently, clinicians must balance the benefits and risks of HRT, with attention to individual risk factors (age and BMI), and choose appropriate therapies directed at specific menopausal symptoms. Patients must be actively involved in the decision process, and understand our limitations as providers to quantify specific risks. Women should be advised that there are no robust data to indicate whether HRT changes the risk of disease recurrence or malignant transformation. Small studies have suggested the possibility of increased recurrence in changes the risk of disease recurrence or malignant transformation.

To minimize the risk of recurrence (Moen et al., 2010; Dunselman et al., 2014), some authors advocate the use of combined HRT for women with a history of endometriosis, to minimize the risk of recurrence (Moen et al., 2010; Dunselman et al., 2014), but there are still risks with combined estrogen-progesterone hormone therapy. These include an elevated risk of breast cancer both during and post-intervention mostly in older women (Chlebowski et al., 2015). Therefore care must be individualized, with the woman’s personal and family history taken into account.

There are many promising areas for future research in this group of women. Our search retrieved no papers on the use of alternative selective estrogen receptor modulators (SERMs) in postmenopausal patients with histories of endometriosis. We are aware of studies testing the gynaecologic safety of SERMs such as ospemifene and bazedoxifene, and combining these agents with oestrogens (especially bazedoxifene/conjugated oestrogens) (Mirkin et al., 2016). Such studies have been promising, and may represent a future alternative to conventional HRT for our cohort.

Summary

Our review highlights an important and severely under-researched area of gynaecology. The prevalence of endometriosis means that both specialists and general practitioners will inevitably encounter women with a history of this condition who are facing the dilemma of managing the menopause. Many women will have suffered years of debilitating symptoms before diagnosis, and then proceeded to undergo multiple treatments and operations in an attempt to regain some quality of life. These women deserve to have accurate, individualized and specific information about the risk of recurrence with different menopausal treatments, so that they can make an informed decision about their care.

Supplementary data

Supplementary data are available at Human Reproduction Update online.

Acknowledgements

The authors would like to thank Dr. Eve Fryer for her advice regarding histopathology.

Authors’ roles

L.C.G. was involved in all parts of the study. K.E.W. sorted articles, performed quality categorization and reviewed manuscript. S.K. performed the search and reviewed the manuscript. K.V. was involved in conceptualization of study and the drafting and review of the manuscript. K.T.Z. was involved in conceptualization of study and the drafting and review of the manuscript. C.M.B. sorted the articles and reviewed the manuscript and was responsible for overall conceptualization of study.

Funding

KTZ and CMB were funded by the European Commission Horizon 2020 research and innovation programme under grant agreement 692065 (project WIDENLIFE). This work was supported by an MRC project grant (MR/K011480/1).

Conflict of interest

No authors have any relevant conflicts of interest to this published work. Outside the submitted work, K.V. reports research grants from Bayer Healthcare and personal fees from Bayer Healthcare and Gruenthal GmbH; K.T.Z. and C.M.B. report research grants from Bayer Healthcare, Volition, Roche Diagnostics and MDNA Life Sciences; C.M.B. has received consultancy fees from ObsEva. The remaining authors report no conflicts of interest outside the submitted work.

References

Abu MA, Sinha P, Totoe L, McCune G. Endometrial cancer thirteen years after total abdominal hysterectomy and bilateral salpingo-ooophorectomy and hormone replacement therapy: a case report. _Eur J Gynaecol Oncol_ 1997; _18_:482–483.

Acién P, Nuñez C, Quereda F, Velasco L, Valiente M, Vidal V. Is a bowel resection necessary for deep endometriosis with rectovaginal or colorectal involvement? _Int J Womens Health_ 2013; _5_:449–455.

Ahn SH, Singh V, Tayade C. Biomarkers in endometriosis: challenges and opportunities. _Fertil Steril_ 2017; _107_:523–532.

Al Kadi H, Hassan S, Al-Fozan HM, Hajeer A. Hormone therapy for endometriosis and surgical menopause. _Cochrane Database Syst Rev_ 2009; Cd005997. doi: 10.1002/14651858.CD005997.pub2.

Al-Talib A, Gilbert L, Arseneau J. Endometrioid adenocarcinoma 13 years after total abdominal hysterectomy and bilateral salpingo-oophorectomy. _Saudi Med J_ 2008; _29_:1044–1047.

Areia A, Sousa V, Frutuoso C, Dias I, Martins MI, de Oliveira CF. Endometrioid adenocarcinoma arising in endometriosis foci six years after estrogen replacement therapy: a case report. _Eur J Gynaecol Oncol_ 2004; _25_:255–256.

Arumugam K, Damodaran P. Endometriosis and estrogen replacement therapy. _Med Sci Res_ 1998; _26_:333–334.

Badawy SZA, Liberatore C, Farhat MA, Valente AL, Landas S. Cervical endometriosis stimulated by estrogen therapy following supracervical hysterectomy. _J Gynecol Surg_ 2004; _19_:141–144.

Bhat RA, Teo M, Bhat AK. Endometriosis after surgical menopause mimicking pelvic malignancy: surgeons’ predicament. _Oman Med J_ 2014; _29_:226–231.

Brooks JJ, Wheeler JE. Malignancy arising in extragonadal endometriosis: a case report and summary of the world literature. _Cancer_ 1977; _40_:3065–3073.

Bulun SE. Endometriosis. _N Engl J Med_ 2009; _360_:268–279.
Bulun SE, Monsavias D, Pavone ME, Dyson M, Xue Q, Attar E, Tokunaga H, Su EJ. Role of estrogen receptor-beta in endometriosis. *Semin Reprod Med* 2012;30:39–45.

Burney RO, Guducic LC. Pathogenesis and pathophysiology of endometriosis. *Fertil Steril* 2012;98:511–519.

Cauley JA, Robbins J, Chen Z, Cummings SR, Jackson RD, LaCroix AZ, LeBoff M, Lewis CE, McGowan J, Neuner J et al. Effects of estrogen plus progesterin on risk of fracture and bone mineral density: the Women’s Health Initiative randomized trial. *JAMA* 2003;290:1729–1738.

Chaine B, Malbranche G, Leong J, Ramon P, Pillie-Leblond I. [Catastrophic hemoptysis during hormone replacement treatment]. *Rev Mal Respir* 2007;24:339–342.

Chilewowski RT, Manson JE, Anderson GL, Cauley JA, Aragaki AK, Stefanick ML, Lane DS, Johnson KC, Wactawski-Wende J, Chen C et al. Estrogen plus progesterin and breast cancer incidence and mortality in the women’s health initiative observational study. *J Natl Cancer Inst* 2013;105:526–535.

Chilewowski RT, Rohan TE, Manson JE, Aragaki AK, Kaunitz A, Stefanick ML, Simon MS, Johnson KC, Wactawski-Wende J, O’ Sullivan MJ et al. Breast cancer after use of estrogen plus progesterin and estrogen alone: analyses of data from 2 women’s health initiative randomized clinical trials. *JAMA Oncol* 2015;1:296–305.

Choi JI, Yoo JG, Kim SJ, Lee HN, Kim MJ. Acute renal failure due to obstructive hydronephrosis resulting from intraluminal obstruction of the ureter by adenosquamous endometrioid carcinoma arising from disseminated endometriosis. *Urolology* 2000;56:331.

Johnson NP, Hummelshoj L, Consortium fWESM. Consensus on current management of endometriosis. *Hum Reprod* 2013;28:1552–1568.

Jones KD, Owen E, Berresford A, Sutton C. Endometrioid adenocarcinoma arising from endometriosis of the rectosigmoid colon. *Gynecol Oncol* 2002;86:220–222.

Joseph J, Reed CE, Sahn SA. Thoracic endometriosis. Recurrence following hysterectomy with bilaparoscopic excision of residual endometriosis. *Fertil Steril* 2009;91:427–430.

Kapadia SB, Russak RR, O’Donnell WF, Harris RN,lecky JW. Postmenopausal ureteral endometriosis with atypical adenomatous hyperplasia following hysterectomy, bilateral oophorectomy, and long-term estrogen therapy. *Ostet Gynecol* 1984;64:60–63s.

Karagjoakar VC, Murphy DJ, Samra JS, Mann CH. Malignant transformation of residual endometriosis after hysterectomy: a case series. *Fertil Steril* 2009;92:1069–1072.

Kawate S, Takeyoshi I, Ikota H, Numaga Y, Sunose Y, Morishita Y. Endometrioid adenocarcinoma arising from endometriosis of the mesentery of the sigmoid colon. *Jpn J Clin Oncol* 2005;35:154–157.

Kitawaki J, Kado N, Ishihara H, Koshiba H, Kitaoka Y, Honjo H. Endometriosis: the pathophysiology as an estrogen-dependent disease. *J Steroid Biochem Mol Biol* 2002;83:149–155.

Klug PW, Mayer HG, Leitner G. [Rare complications of endometriosis—2 case reports]. *Geburtshilfe Frauenheilkd* 1987;47:870–871.

Kuh D, Muthuri S, Cooper R, Mackinnon K, Cooper C, Adams JE, Hardy R, Ward KA. Menopause, reproductive life, hormone replacement therapy, and bone phenotype at age 60–64 years: a British birth cohort. *J Clin Endocrinol Metab* 2016;101:3827–3837.

Langer RD. The evidence base for HRT: what can we believe? *Climacteric* 2017;20:91–96.

Leiserowitz GS, Gumbs JJ, Ol R, Dalrymple JL, Smith LH, Ryu J, Scudder S, Russell RJ, Booth HW. The role of estrogen plus progestin and estrogen alone: analyses of data from 2 women’s health initiative randomized clinical trials. *JAMA* 2003;290:1729–1738.

Leiserowitz GS, Gumbs JL, Oi R, Dalrymple JL, Smith LH, Ryu J, Scudder S, Russell RJ, Booth HW. The role of estrogen plus progestin and estrogen alone: analyses of data from 2 women’s health initiative randomized clinical trials. *JAMA Oncol* 2015;1:296–305.
postmenopausal hormone-replacement therapy on estimated structural bone strength: a study in discordant monozygotic twins. J Bone Miner Res 2011;26:546–552.

Milam MR, Atkinson JB, Currie JL. Adenomasarcoma arising in inguinal endometriosis. Obstet Gynecol 2006;108:753–755.

Mirkin S, Pinkerton JV, Kagan R, Thompson JR, Pan K, Pickar JH, Komms BS, Archer DF. Gynecologic safety of conjugated estrogens plus bazedoxifene: pooled analysis of five phase 3 trials. J Womens Health (Larchmt) 2016;25:431–442.

Moen MH, Rees M, Brincat M, Erel T, Gambacciani M, Lambrinoudaki I, Schenck-Gustafsson K, Trenollieres F, Vujovic S, Rozenberg S. EMAS position statement: managing the menopause in women with a past history of endometriosis. Maturitas 2010;67:94–97.

Montamedi. Endometrioid adenocarcinoma in endometriosis of the ureter. A case report. Geburtshilfe Frauenheilkd 2002;62:490–494.

Mousey AL, Wilgus A, Slawson DC. Diagnosis and management of endometriosis. Am Fam Physician 2006;74:594–600.

Munksgaard PS, Blaakjer J. The association between endometriosis and ovarian cancer: a review of histological, genetic and molecular alterations. Gynecol Oncol 2012;124:164–169.

Nessfat F, Apostol R, Mahmoud M, el Daoouk M. Malignant transformation of endometriosis and its clinical significance. Fertil Steril 2014;102:342–344.

Noel JC, Anaf V, Fay I, Wespes E. Ureteral mullerian carcinomas (mixed mullerian tumor) associated with endometriosis occurring in a patient with a concentrated soy isoflavones supplementation. Arch Gynecol Obstet 2006;274:389–392.

Oxlholm D, Knudsen UB, Kryger-Baggesen N, Ravn P. Postmenopausal endometriosis. Acta Obstet Gynecol Scand 2007;86:1158–1164.

Parker WH, Broder MS, Chang E, Feskanich D, Farquhar C, Liu Z, Shoupe D, Milam MR, Atkinson JB, Currie JL. Adenosarcoma arising in inguinal endometriosis. Obstet Gynecol Reprod Med 2010;S1:119–120.

Powell JL, Connor GP, Henderson GS. Androgen-producing, atypically proliferating endometriosis. Acta Obstet Gynecol Scand 2005;84:292–298.

Punnonen R, Klemi PJ, Harris HR, Randall JC, Prokopenko I, Nyholt DR, Morris AP, Montgomery GW. Postmenopausal endometriosis: a study in discordant monozygotic twins. Hum Mol Genet 2011a;20:118–119.

Rahmioglu N, Macgregor S, Drong AW, Hedman AK, Harris HR, Randall JC, Prokopenko I, Nyholt DR, Morris AP, Montgomery GW. Postmenopausal endometriosis. J Bone Miner Res 2001;16:283–289.

Rahmioglu N, Macgregor S, Drong AW, Hedman AK, Harris HR, Randall JC, Prokopenko I, Nyholt DR, Morris AP, Montgomery GW. Postmenopausal endometriosis: a report of recurrent endometriosis following Tibolone hormone replacement therapy. J Obstet Gynaecol 2007;27:433–434.

Rocca WA, Bower JH, Maraganore DM, Ahlskog JE, Grossardt BR, de Andrade M. Review Manager (RevMan) [Computer program]. Version 5.3. 2014. The Nordic Cochrane Center, The Cochrane Collaboration, Copenhagen.

Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial. JAMA 2002;288:321–333.